- Home
- ELUT vs LITS Comparison
ELUT vs LITS Comparison
Compare ELUT & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELUT | LITS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 36.3M |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ELUT | LITS |
|---|---|---|
| Price | $0.85 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.7K | ★ 255.7K |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | 13.81 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $12,293,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.69 |
| 52 Week High | $1.39 | $2.15 |
Technical Indicators
Market Signals| Indicator | ELUT | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 37.27 |
| Support Level | $0.75 | $0.89 |
| Resistance Level | $0.87 | $1.05 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 74.04 | 0.90 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.